The M. D. Anderson Cancer Center Administrative Core Facility will serve as a nexus for this SPORE in Multiple Myeloma as the latter strives to develop novel approaches to the prevention, early detection, diagnosis, staging, and treatment of this hematologic malignancy. This Core's overall goals will be to provide coordination and oversight of SPORE activities, to facilitate internal and external collaborations as well as intramural and extramural communications, and to thereby expedite in every way possible the translational mission ofthe SPORE.
Specific aims of this Core will include: 1. To assure the overall scientific quality and function of all of the SPORE components, including the five Projects, six Cores, and the Developmental Research and Career Development Programs;2. To establish and monitor compliance of SPORE activities with all applicable local, state, national, and international regulations and requirements;3. To oversee SPORE expenditures, and maintain and distribute budget information on a regular basis;4. To organize and convene all necessary SPORE meetings, including those ofthe Internal and External Advisory Boards, utilizing the M. D. Anderson conference and videoconference capabilities, and provide summaries thereof to applicable personnel;5. To assist the SPORE Developmental Research Program and Career Development Program Directors and Co-Directors in administering these vital components;6. To support the preparation of all SPORE publications and other external communications;7. To coordinate, obtain, and maintain Institutional commitments to the SPORE from the participating centers;8. To encourage and facilitate intraand inter-SPORE communications, collaborations, and data and resource sharing;and 9. To promote communications and collaborations with other SPORE partners in both academia and industry. Through these activities, the Administrative Core will help both established and developmental projects clearly focus on their translational goals, and to identify and implement steps required to translate the research to and from the clinic to produce objective evidence of improving clinically relevant endpoints in multiple myeloma.

Public Health Relevance

The Administrative Core Facility will play the central role on this SPORE in helping both established and developmental projects clearly focus on their translational goals, and to identify and implement steps required to translate the research to and from the clinic to produce objective evidence of improving outcomes in multiple myeloma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA142509-03
Application #
8380824
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
3
Fiscal Year
2012
Total Cost
$65,491
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Jun; Medeiros, L Jeffrey; Young, Ken H (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 8:351
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Zhou, Liang; Zhang, Yu; Sampath, Deepak et al. (2018) Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118:388-397
Davenport, Clemontina A; Maity, Arnab; Baladandayuthapani, Veerabhadran (2018) Functional interaction-based nonlinear models with application to multiplatform genomics data. Stat Med 37:2715-2733
Yao, Z; Deng, L; Xu-Monette, Z Y et al. (2018) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:353-363
Zhang, Xiaohui; Lee, Hans C; Shirazi, Fazal et al. (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:2224-2239
Thomas, Sheeba K; Cha, Soung-Chul; Smith, D Lynne et al. (2018) Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18:187
Xu-Monette, Zijun Y; Zhou, Jianfeng; Young, Ken H (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68-83
Wan, Wen; Pei, Xin-Yan; Grant, Steven et al. (2017) Nonlinear response surface in the study of interaction analysis of three combination drugs. Biom J 59:9-24
Nguyen, Tri; Parker, Rebecca; Hawkins, Elisa et al. (2017) Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget 8:31478-31493

Showing the most recent 10 out of 203 publications